Coherus Shakes Up Ranibizumab Competition With First Interchangeable US Biosimilar
Cimerli Version Approved By FDA For All Five Indications Of Lucentis Reference Product
Coherus has the first US interchangeable Lucentis biosimilar • Source: Shutterstock 
